REMICADE R infliximab Clinical
Selected Abstract
REMICADE(R) (infliximab) Clinical Studies in Psoriasis to be Presented at 14th European Academy of Dermatology and Venereology (EADV) Annual Congress.
LONDON, October 11 /PRNewswire/ -- Overview: The TNF-alpha inhibitor, REMICADE(R) (infliximab), is proven effective in treating patients with moderate-to-severe plaque psoriasis and is setting new standards for skin clearance. Psoriasis is a chronic skin disorder marked by periodic flare-ups of ... October 11, 2005; PR Newswire Europe
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
REMICADE(R) (infliximab) Clinical Studies in Psoriasis to be Presented at 14th European Academy of Dermatology and Venereology (EADV) Annual Congress.
2.
New Phase III Data Shows Abbott's HUMIRA(R) (Adalimumab) Induced Clinical Remission In Patients With Crohn's Disease Who Lost Response to, or Were Intolerant to, Remicade(R) (Infliximab).(Clinical report)
|
